Press releases - Median Technologies

Assistance Publique – Hôpitaux de Paris (AP-HP) and Median Technologies reach a research collaboration agreement involving the iBiopsy® platform. The collaboration agreement initially covers two joint clinical studies on liver cancer, involving coordinating investigators from two AP-HP hospitals -Pitié-Salpêtrière and Paul-Brousse-, and Median’s team. The agreement will enable Median to work with large patient cohorts for the clinical validation of iBiopsy®’s AI technologies.

2019 full year revenue of €9 million, increased by 41% compared to 2018 full year revenue
Order backlog of €38.3 million, increased by 24.8% compared to end of H1 2019 and by 61.6% compared to end of 2018
Cash and cash equivalents of €7.6 million

Median Technologies announces the signing of a € 35 million finance contract with the European Investment Bank (EIB). This finance contract will enable Median Technologies to accelerate its investment program for the iBiopsy® imaging phenomics platform. Median expects the disbursement of the first tranche of € 15 million during the first semester of 2020.

Median Technologies’ Q3 performance shows steady growth, validates the strategy adopted in 2018 (unaudited figures). As of September 30th, 2019, cumulated revenue of € 6.3 million, already matching total revenue made in 2018 – Q3 revenue of € 2.3 million, a steady increase over the last four quarters – Order backlog of € 35.9 million, up 17% since June 30th, 2019 – Cash and cash equivalents of € 8.3 million, an increase compared to June 30th, 2019